Karuna Therapeutics Stock Shares Owned By Insiders

Karuna Therapeutics fundamentals help investors to digest information that contributes to Karuna Therapeutics' financial success or failures. It also enables traders to predict the movement of Karuna Stock. The fundamental analysis module provides a way to measure Karuna Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Karuna Therapeutics stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Karuna Therapeutics Company Shares Owned By Insiders Analysis

Karuna Therapeutics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Insiders Shares

 = 

Executives Shares

+

Employees

More About Shares Owned By Insiders | All Equity Analysis

Current Karuna Therapeutics Shares Owned By Insiders

    
  4.98 %  
Most of Karuna Therapeutics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Karuna Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Competition

Based on the latest financial disclosure, 4.98% of Karuna Therapeutics are shares owned by insiders. This is 67.19% lower than that of the Biotechnology sector and 64.88% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 50.64% higher than that of the company.

Karuna Shares Owned By Insiders Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Karuna Therapeutics' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Karuna Therapeutics could also be used in its relative valuation, which is a method of valuing Karuna Therapeutics by comparing valuation metrics of similar companies.
Karuna Therapeutics is currently under evaluation in shares owned by insiders category among its peers.

Karuna Fundamentals

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Other Consideration for investing in Karuna Stock

If you are still planning to invest in Karuna Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Karuna Therapeutics' history and understand the potential risks before investing.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Fundamental Analysis
View fundamental data based on most recent published financial statements
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities